Erasca Dividende
Dividende contrôle des critères 0/6
Erasca does not have a record of paying a dividend.
Informations clés
n/a
Rendement du dividende
-28.5%
Rendement des rachats
Rendement total pour l'actionnaire | -28.5% |
Rendement futur des dividendes | 0% |
Croissance des dividendes | n/a |
Prochaine date de paiement du dividende | n/a |
Date ex-dividende | n/a |
Dividende par action | n/a |
Ratio de distribution | n/a |
Mises à jour récentes des dividendes
Pas de mise à jour
Recent updates
We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth
Oct 15Erasca: New Focus After Restructuring, But Need More Differentiation
Sep 30Is Erasca (NASDAQ:ERAS) In A Good Position To Deliver On Growth Plans?
Feb 21We Think Erasca (NASDAQ:ERAS) Needs To Drive Business Growth Carefully
Nov 16Companies Like Erasca (NASDAQ:ERAS) Are In A Position To Invest In Growth
Jun 28We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth
Jan 20Erasca forms clinical trial partnership with Pfizer for cancer therapy
Oct 20Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation
Sep 23Erasca adds 10% ahead of R&D Day
Sep 07Erasca, Eli Lilly to collaborate on trial to evaluate combo treatment for two cancers
Jul 18We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate
Apr 12Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation
Dec 28Stabilité et croissance des paiements
Récupération des données sur les dividendes
Dividende stable: Insufficient data to determine if ERAS's dividends per share have been stable in the past.
Dividende croissant: Insufficient data to determine if ERAS's dividend payments have been increasing.
Rendement des dividendes par rapport au marché
Erasca Rendement des dividendes par rapport au marché |
---|
Segment | Rendement du dividende |
---|---|
Entreprise (ERAS) | n/a |
25% du marché (US) | 1.5% |
25% du marché (US) | 4.5% |
Moyenne du secteur (Biotechs) | 2.2% |
Analyste prévisionnel (ERAS) (jusqu'à 3 ans) | 0% |
Dividende notable: Unable to evaluate ERAS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Dividende élevé: Unable to evaluate ERAS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Bénéfice distribué aux actionnaires
Couverture des revenus: Insufficient data to calculate ERAS's payout ratio to determine if its dividend payments are covered by earnings.
Paiement en espèces aux actionnaires
Couverture des flux de trésorerie: Unable to calculate sustainability of dividends as ERAS has not reported any payouts.